US biopharma Aerpio Therapeutics clinches $27m Series A

Clinical‐stage biopharmaceutical company Aerpio Therapeutics has closed a $27m Series A financing led by life sciences investor Novartis BioVentures and joined by Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and AgeChem Venture Fund.